Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non-cirrhotic hepatitis C patients
Intradermal vaccination has been proposed as an alternative for the administration of anti-hepatitis B vaccine. Patients ( n=66) with chronic viral hepatitis C without cirrhosis were randomised into two groups (intramuscular, n=38; and intradermal, n=28) for prospective immunisation with 20 μg recom...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2003-06, Vol.21 (21), p.2747-2750 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2750 |
|---|---|
| container_issue | 21 |
| container_start_page | 2747 |
| container_title | Vaccine |
| container_volume | 21 |
| creator | Arbizu, Eduardo Albéniz Marugán, Rafael Bárcena Grijalba, Javier Yuste Serrano, Pilar López Grande, Luis Gil Del Campo Terrón, Santos |
| description | Intradermal vaccination has been proposed as an alternative for the administration of anti-hepatitis B vaccine. Patients (
n=66) with chronic viral hepatitis C without cirrhosis were randomised into two groups (intramuscular,
n=38; and intradermal,
n=28) for prospective immunisation with 20
μg recombinant vaccine, using an ultra-rapid schedule (doses at 0, 15 and 30 days). Sero-conversion (antibody level ≥10
mU/ml) in the intramuscular group was reached by 20, 40 and 72% of patients at days 15, 30 and 60 compared to 4, 8 and 36% for the intradermal group (
P=0.010 at day 60). Additionally, levels rose more rapidly in the intramuscular group (
P=0.004). Our results do not support the use of intradermal route of immunisation against HBV in HCV patients. |
| doi_str_mv | 10.1016/S0264-410X(03)00221-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73375900</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03002214</els_id><sourcerecordid>18775356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-8bc4970ecbaa29395490d65b58ce06db70038e184ba4c71fea15fb67653cded93</originalsourceid><addsrcrecordid>eNqFkc9rFDEcxYNY7Lb6JygBsehhajL5fRJd1BYKPajgLWQy36EpM5ltklnwvzfbXVzw0lPC4_MeyXsIvabkkhIqP_4greQNp-T3e8I-ENK2tOHP0IpqxZpWUP0crf4hp-gs53tCiGDUvECntFVGS8pW6OE6luSmJftldAlvIeUl47ATe0iTG7HrpxBDrkIJc8TzgF0sobmDTRVKyPgL3jrvQ4Rqw3GOjQ8p3c0leHyE1nh3g1jyS3QyuDHDq8N5jn59-_pzfdXc3H6_Xn--aTwXpDS689woAr5zrjXMCG5IL0UntAci-04RwjRQzTvHvaIDOCqGTiopmO-hN-wcXexzN2l-WCAXO4XsYRxdhHnJVjGmhKkpT4G1USWYkBV8-x94Py8p1k9Yyo2UXGvVVkrsKZ_mnBMMdpPC5NIfS4ndTWcfp7O7XSxh9nE6y6vvzSF96Sboj67DVhV4dwBc9m4ckos-5CPHtRRG0Mp92nNQ290GSDb72ryHPiTwxfZzeOIpfwFRS7cu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1496648872</pqid></control><display><type>article</type><title>Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non-cirrhotic hepatitis C patients</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Arbizu, Eduardo Albéniz ; Marugán, Rafael Bárcena ; Grijalba, Javier Yuste ; Serrano, Pilar López ; Grande, Luis Gil ; Del Campo Terrón, Santos</creator><creatorcontrib>Arbizu, Eduardo Albéniz ; Marugán, Rafael Bárcena ; Grijalba, Javier Yuste ; Serrano, Pilar López ; Grande, Luis Gil ; Del Campo Terrón, Santos</creatorcontrib><description>Intradermal vaccination has been proposed as an alternative for the administration of anti-hepatitis B vaccine. Patients (
n=66) with chronic viral hepatitis C without cirrhosis were randomised into two groups (intramuscular,
n=38; and intradermal,
n=28) for prospective immunisation with 20
μg recombinant vaccine, using an ultra-rapid schedule (doses at 0, 15 and 30 days). Sero-conversion (antibody level ≥10
mU/ml) in the intramuscular group was reached by 20, 40 and 72% of patients at days 15, 30 and 60 compared to 4, 8 and 36% for the intradermal group (
P=0.010 at day 60). Additionally, levels rose more rapidly in the intramuscular group (
P=0.004). Our results do not support the use of intradermal route of immunisation against HBV in HCV patients.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(03)00221-4</identifier><identifier>PMID: 12798613</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Age ; Biological and medical sciences ; Female ; Fundamental and applied biological sciences. Psychology ; HBV-vaccine ; Hepatitis ; Hepatitis B - complications ; Hepatitis B - immunology ; Hepatitis B - prevention & control ; Hepatitis B Vaccines - administration & dosage ; Hepatitis B Vaccines - adverse effects ; Hepatitis C ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - immunology ; Human viral diseases ; Humans ; Immunization ; Immunization Schedule ; Infections ; Infectious diseases ; Injections, Intradermal ; Injections, Intramuscular ; Intradermal ; Intramuscular ; Liver cirrhosis ; Liver diseases ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Vaccination ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Viral diseases ; Viral hepatitis ; Virology</subject><ispartof>Vaccine, 2003-06, Vol.21 (21), p.2747-2750</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2003 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jun 20, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-8bc4970ecbaa29395490d65b58ce06db70038e184ba4c71fea15fb67653cded93</citedby><cites>FETCH-LOGICAL-c450t-8bc4970ecbaa29395490d65b58ce06db70038e184ba4c71fea15fb67653cded93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1496648872?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002,64392,64394,64396,72476</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14865951$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12798613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arbizu, Eduardo Albéniz</creatorcontrib><creatorcontrib>Marugán, Rafael Bárcena</creatorcontrib><creatorcontrib>Grijalba, Javier Yuste</creatorcontrib><creatorcontrib>Serrano, Pilar López</creatorcontrib><creatorcontrib>Grande, Luis Gil</creatorcontrib><creatorcontrib>Del Campo Terrón, Santos</creatorcontrib><title>Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non-cirrhotic hepatitis C patients</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Intradermal vaccination has been proposed as an alternative for the administration of anti-hepatitis B vaccine. Patients (
n=66) with chronic viral hepatitis C without cirrhosis were randomised into two groups (intramuscular,
n=38; and intradermal,
n=28) for prospective immunisation with 20
μg recombinant vaccine, using an ultra-rapid schedule (doses at 0, 15 and 30 days). Sero-conversion (antibody level ≥10
mU/ml) in the intramuscular group was reached by 20, 40 and 72% of patients at days 15, 30 and 60 compared to 4, 8 and 36% for the intradermal group (
P=0.010 at day 60). Additionally, levels rose more rapidly in the intramuscular group (
P=0.004). Our results do not support the use of intradermal route of immunisation against HBV in HCV patients.</description><subject>Age</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>HBV-vaccine</subject><subject>Hepatitis</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B Vaccines - administration & dosage</subject><subject>Hepatitis B Vaccines - adverse effects</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - immunology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Schedule</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Injections, Intradermal</subject><subject>Injections, Intramuscular</subject><subject>Intradermal</subject><subject>Intramuscular</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc9rFDEcxYNY7Lb6JygBsehhajL5fRJd1BYKPajgLWQy36EpM5ltklnwvzfbXVzw0lPC4_MeyXsIvabkkhIqP_4greQNp-T3e8I-ENK2tOHP0IpqxZpWUP0crf4hp-gs53tCiGDUvECntFVGS8pW6OE6luSmJftldAlvIeUl47ATe0iTG7HrpxBDrkIJc8TzgF0sobmDTRVKyPgL3jrvQ4Rqw3GOjQ8p3c0leHyE1nh3g1jyS3QyuDHDq8N5jn59-_pzfdXc3H6_Xn--aTwXpDS689woAr5zrjXMCG5IL0UntAci-04RwjRQzTvHvaIDOCqGTiopmO-hN-wcXexzN2l-WCAXO4XsYRxdhHnJVjGmhKkpT4G1USWYkBV8-x94Py8p1k9Yyo2UXGvVVkrsKZ_mnBMMdpPC5NIfS4ndTWcfp7O7XSxh9nE6y6vvzSF96Sboj67DVhV4dwBc9m4ckos-5CPHtRRG0Mp92nNQ290GSDb72ryHPiTwxfZzeOIpfwFRS7cu</recordid><startdate>20030620</startdate><enddate>20030620</enddate><creator>Arbizu, Eduardo Albéniz</creator><creator>Marugán, Rafael Bárcena</creator><creator>Grijalba, Javier Yuste</creator><creator>Serrano, Pilar López</creator><creator>Grande, Luis Gil</creator><creator>Del Campo Terrón, Santos</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20030620</creationdate><title>Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non-cirrhotic hepatitis C patients</title><author>Arbizu, Eduardo Albéniz ; Marugán, Rafael Bárcena ; Grijalba, Javier Yuste ; Serrano, Pilar López ; Grande, Luis Gil ; Del Campo Terrón, Santos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-8bc4970ecbaa29395490d65b58ce06db70038e184ba4c71fea15fb67653cded93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Age</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>HBV-vaccine</topic><topic>Hepatitis</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B Vaccines - administration & dosage</topic><topic>Hepatitis B Vaccines - adverse effects</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - immunology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Schedule</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Injections, Intradermal</topic><topic>Injections, Intramuscular</topic><topic>Intradermal</topic><topic>Intramuscular</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arbizu, Eduardo Albéniz</creatorcontrib><creatorcontrib>Marugán, Rafael Bárcena</creatorcontrib><creatorcontrib>Grijalba, Javier Yuste</creatorcontrib><creatorcontrib>Serrano, Pilar López</creatorcontrib><creatorcontrib>Grande, Luis Gil</creatorcontrib><creatorcontrib>Del Campo Terrón, Santos</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arbizu, Eduardo Albéniz</au><au>Marugán, Rafael Bárcena</au><au>Grijalba, Javier Yuste</au><au>Serrano, Pilar López</au><au>Grande, Luis Gil</au><au>Del Campo Terrón, Santos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non-cirrhotic hepatitis C patients</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2003-06-20</date><risdate>2003</risdate><volume>21</volume><issue>21</issue><spage>2747</spage><epage>2750</epage><pages>2747-2750</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Intradermal vaccination has been proposed as an alternative for the administration of anti-hepatitis B vaccine. Patients (
n=66) with chronic viral hepatitis C without cirrhosis were randomised into two groups (intramuscular,
n=38; and intradermal,
n=28) for prospective immunisation with 20
μg recombinant vaccine, using an ultra-rapid schedule (doses at 0, 15 and 30 days). Sero-conversion (antibody level ≥10
mU/ml) in the intramuscular group was reached by 20, 40 and 72% of patients at days 15, 30 and 60 compared to 4, 8 and 36% for the intradermal group (
P=0.010 at day 60). Additionally, levels rose more rapidly in the intramuscular group (
P=0.004). Our results do not support the use of intradermal route of immunisation against HBV in HCV patients.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>12798613</pmid><doi>10.1016/S0264-410X(03)00221-4</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2003-06, Vol.21 (21), p.2747-2750 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73375900 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Age Biological and medical sciences Female Fundamental and applied biological sciences. Psychology HBV-vaccine Hepatitis Hepatitis B - complications Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - adverse effects Hepatitis C Hepatitis C, Chronic - complications Hepatitis C, Chronic - immunology Human viral diseases Humans Immunization Immunization Schedule Infections Infectious diseases Injections, Intradermal Injections, Intramuscular Intradermal Intramuscular Liver cirrhosis Liver diseases Male Medical sciences Microbiology Middle Aged Vaccination Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Viral diseases Viral hepatitis Virology |
| title | Intramuscular versus intradermal administration of anti-hepatitis B vaccine in non-cirrhotic hepatitis C patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T18%3A09%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intramuscular%20versus%20intradermal%20administration%20of%20anti-hepatitis%20B%20vaccine%20in%20non-cirrhotic%20hepatitis%20C%20patients&rft.jtitle=Vaccine&rft.au=Arbizu,%20Eduardo%20Alb%C3%A9niz&rft.date=2003-06-20&rft.volume=21&rft.issue=21&rft.spage=2747&rft.epage=2750&rft.pages=2747-2750&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(03)00221-4&rft_dat=%3Cproquest_cross%3E18775356%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1496648872&rft_id=info:pmid/12798613&rft_els_id=S0264410X03002214&rfr_iscdi=true |